Phenylalanine hydroxylase deficiency treatment and management: A systematic evidence review of the American College of Medical Genetics and Genomics (ACMG)
Genetics in Medicine · 2023-09 · 25 (9) · 100358
DOI: 10.1016/j.gim.2022.12.005 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Genetics in Medicine, 2023-09. Verfasst von April D Adams und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX; Division of Maternal-Fetal Medicine, Department of Molecular and Hu…. Hauptthemen laut MEDLINE: Genetics, Medical, Phenylketonurias, Phenylalanine Hydroxylase, Phenylketonuria, Maternal. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 150 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Elevated serum phenylalanine (Phe) levels due to biallelic pathogenic variants in phenylalanine hydroxylase (PAH) may cause neurodevelopmental disorders or birth defects from maternal phenylketonuria. New Phe reduction treatments have been approved in the last decade, but uncertainty on the optimal lifespan goal Phe levels for patients with PAH deficiency remains. METHODS: We searched Medline and Embase for evidence of treatment concerning PAH deficiency up to September 28, 2021. Risk of bias was evaluated based on study design. Random-effects meta-analyses were performed to compare IQ, gestational outcomes, and offspring outcomes based on Phe ≤ 360 μmol/L vs > 360 μmol/L and reported as odds ratio and 95% CI. Remaining results were narratively synthesized. RESULTS: A total of 350 studies were included. Risk of bias was moderate. Lower Phe was consistently associated with better outcomes. Achieving Phe ≤ 360 μmol/L before conception substantially lowered the risk of negative effect to offspring in pregnant individuals (odds ratio = 0.07, 95% CI = 0.04-0.14; P < .0001). Adverse events due to pharmacologic treatment were common, but medication reduced Phe levels, enabling dietary liberalization. CONCLUSIONS: Reduction of Phe levels to ≤360 μmol/L through diet or medication represents effective interventions to treat PAH deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX; Division of Maternal-Fetal Medicine, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX.
- Programa de Maestría y Doctorado en Ciencias Médicas, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico; Laboratorio de Citogenética, Instituto Nacional de Pediatría, Mexico City, Mexico.
- Southern California Kaiser Permanente, Downey, CA.
- American College of Medical Genetics and Genomics, Bethesda, MD.
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY.
- University of Utah School of Medicine, Salt Lake City, UT; ARUP Laboratories, Salt Lake City, UT.
Zitieren
APA
Adams, A. D., Fiesco-Roa, M. Ó., Wong, L., Jenkins, G. P., Malinowski, J., Demarest, O. M., Rothberg, P. G., Hobert, J. A., & ACMG Therapeutics Committee. Electronic address: documents@acmg.net (2023). Phenylalanine hydroxylase deficiency treatment and management: A systematic evidence review of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 25(9), 100358. https://doi.org/10.1016/j.gim.2022.12.005
Vancouver
Adams AD, Fiesco-Roa MÓ, Wong L, Jenkins GP, Malinowski J, Demarest OM, et al. Phenylalanine hydroxylase deficiency treatment and management: A systematic evidence review of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. 2023;25(9):100358. doi:10.1016/j.gim.2022.12.005
BibTeX
@article{Adams2023,
author = {Adams, April D and Fiesco-Roa, Moisés Ó and Wong, Lawrence and Jenkins, Gabrielle P and Malinowski, Jennifer and Demarest, Olivia M and Rothberg, Paul G and Hobert, Judith A and ACMG Therapeutics Committee. Electronic address: documents@acmg.net, ACMG Therapeutics Committee. Electronic address: documents@acmg.net},
title = {Phenylalanine hydroxylase deficiency treatment and management: A systematic evidence review of the American College of Medical Genetics and Genomics (ACMG)},
journal = {Genetics in Medicine},
year = {2023},
volume = {25},
number = {9},
pages = {100358},
doi = {10.1016/j.gim.2022.12.005}
}
EUVIMED